Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q4 CY2025, but sales fell by 1.2% ...

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

Management indicated full year revenue is expected to align with broader market expectations Non GAAP earnings per share ...

PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to ...

Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s recent game plan. Cramer had mixed feelings about the stock, as he stated: On the other hand, I worry about Pfizer because while its stock ...

Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share ...

Pfizer (NYSE: PFE) posted fourth-quarter 2025 revenue of about $18 billion, down 1% from the year-ago quarter, and adjusted ...

Analysts expect Pfizer’s revenue to decrease approximately 5% to around $16.95 billion, while adjusted earnings per share are projected to fall 9.5% to 57 cents compared to 63 cents in the same period ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer beat analysts’ revenue expectations by 0.6% last quarter, reporting revenues of $16.65 billion, down 5.9% year on year ...

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...